Goldman Sachs organized a China biotech field trip, meeting with key companies like Hengrui, Hansoh, and Kelun-Biotech, reinforcing a positive sector view.
China's biotech sector is shifting from me-too drugs to true innovation, with government backing, making it a hot investment theme.
Free preview — more China A-share & HK research · About Us · Legal & Privacy